kim_sinil_4

Mirna appoints ex-Pfizer senior director

pharmafile | June 6, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing Pfizer, miRNA 

Biotech firm Mirna Therapeutics has appointed Dr Sinil Kim as vice president of Oncology and chief medical officer.

Kim will be responsible for directing clinical development of the firm’s first cancer product candidate as well as advancing the company’s micro-RNA pipeline.

“Dr Kim joins Mirna at an exciting time in our company’s growth as we have just successfully initiated our MRX34 Phase I trial and are looking forward to further growth and maturation of our proprietary micro-RNA discovery platform and preclinical pipeline” said Paul Lammers, president and chief executive of Mirna.

Advertisement

Prior to joining Mirna Kim was most recently a senior director at Pfizer in the US where he served as the Global Clinical lead for Inlyta and Torisel programmes.

Previously Kim served as director of Clinical Oncology at Bristol-Myers Squibb where he worked on the clinical development of Erbitux. He was also the co-founder of DepoTech in San Diego where he invented several liposomal drug products.

“The field of micro-RNA based therapeutics has expanded exponentially over the past few years and shows great promise in the fight against cancer,” said Kim.

“I am excited to join the Mirna team and look forward to advancing MRX34 the first tumour suppressor miRNA to reach the clinic through the development process as a critically needed potentially new approach to treat cancer.”

Related Content

NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

Vaccine image

Pfizer releases results for severe RSV-associated LRTD treatment study

US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …

New Real-World Data Published in Journal of Cardiac Failure on Effectiveness

Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …

The Gateway to Local Adoption Series

Latest content